进入2025年,药企们出售一些业务的消息接踵而至。2025年1月7日上午,和黄医药(00013.HK)举办了线上投资者和分析师会议,回应了公司出售非核心合资企业上海和黄药业45%股权后原因以及后续研发计划。上海和黄药业原本是和黄医药和上海医药于2001年以50:50的比例成立的合资企业,也是上海首家中药合资企业,主营自有品牌心血管药物麝香保心丸,该公司目前在口服心血管中药市场份额超过25%。这次...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.